PMID- 12508144
OWN - NLM
STAT- MEDLINE
DCOM- 20030130
LR  - 20130524
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 187
IP  - 1
DP  - 2003 Jan 1
TI  - Predictive value of provirus load and DNA human immunodeficiency virus genotype 
      for successful abacavir-based simplified therapy.
PG  - 38-46
AB  - Of 75 human immunodeficiency virus (HIV) type 1-infected patients successfully 
      responding to 2 nucleoside reverse-transcriptase inhibitors (NRTIs) plus 1 
      protease inhibitor (PI), 55 started a simplified abacavir (ABC)-based triple NRTI 
      regimen. Influences of DNA load and DNA reverse-transcriptase (RT) mutations on 
      virological responses were assessed at month 6 after initiation of therapy. 
      Baseline heterogeneity was observed: peripheral blood mononuclear cell (PBMC) 
      genotyping showed 31% RT mutations with 1-5 NRTI-related mutations, 78% protease 
      mutations had 1-5 PI-related mutations; and HIV-1-DNA levels were 1.8-3.5 log(10) 
      copies/10(6) PBMC. Outcomes for 49 patients on a regimen of 2 NRTIs plus ABC were 
      as follows: 22 successes, 10 blips ("blip" defined as intermittent plasma HIV-1 
      RNA levels between 50 and 100 copies/mL and a return to an undetectable level), 
      and 17 failures, whereas, for patients continuing on a regimen of 2 NRTIs plus 1 
      PI, there were 19 successes and 1 blip. Previous treatment regimens, baseline 
      provirus level, and PBMC genotype predicted virological outcome.
FAU - Pellegrin, Isabelle
AU  - Pellegrin I
AD  - Department of Virology, Bordeaux University Hospital, France. 
      isabelle.pellegrin@chu-bordeaux.fr
FAU - Caumont, Anne
AU  - Caumont A
FAU - Garrigue, Isabelle
AU  - Garrigue I
FAU - Merel, Patrick
AU  - Merel P
FAU - Schrive, Marie-Helene
AU  - Schrive MH
FAU - Fleury, Herve
AU  - Fleury H
FAU - Dupon, Michel
AU  - Dupon M
FAU - Pellegrin, Jean-Luc
AU  - Pellegrin JL
FAU - Ragnaud, Jean-Marie
AU  - Ragnaud JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20021213
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (DNA, Viral)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (HIV Protease Inhibitors)
RN  - 0 (RNA, Viral)
RN  - EC 2.7.7.49 (HIV Reverse Transcriptase)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/*drug therapy/virology
MH  - Adult
MH  - Antiretroviral Therapy, Highly Active
MH  - DNA, Viral/*analysis
MH  - Dideoxynucleosides/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genotype
MH  - HIV Protease Inhibitors/administration & dosage
MH  - HIV Reverse Transcriptase/*genetics
MH  - HIV-1/*genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - RNA, Viral/blood
MH  - Viral Load
EDAT- 2003/01/01 04:00
MHDA- 2003/01/31 04:00
CRDT- 2003/01/01 04:00
PHST- 2002/06/14 00:00 [received]
PHST- 2002/09/05 00:00 [revised]
PHST- 2003/01/01 04:00 [pubmed]
PHST- 2003/01/31 04:00 [medline]
PHST- 2003/01/01 04:00 [entrez]
AID - JID020713 [pii]
AID - 10.1086/345860 [doi]
PST - ppublish
SO  - J Infect Dis. 2003 Jan 1;187(1):38-46. doi: 10.1086/345860. Epub 2002 Dec 13.